FDA Guides Post-Market Watch on Gene Therapy Wonders
Published Date: 9/25/2025
Notice
Summary
The FDA just dropped a draft guide to help companies track how safe and effective cell and gene therapies are after they hit the market. This is big for drug makers because these therapies can have long-lasting effects, and we need to keep an eye on them beyond initial tests. Companies should get ready to collect and share ongoing data, which might mean extra work and costs down the road.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Drug Makers Must Track CGT Data
The FDA’s draft guidance tells companies that make cell and gene therapy (CGT) products to collect and share safety and effectiveness data after approval. The guidance says firms should be ready to perform ongoing postapproval studies and data collection, which the notice says may mean extra work and additional costs for companies.
More Long-Term Safety Data for Patients
The draft guidance emphasizes collecting postapproval study data for cell and gene therapy products to gather information on product safety and effectiveness over time. This means patients and clinicians may get more long-term safety and effectiveness information about CGT products after they reach the market.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in